Next |
home / stock / apto / apto message board
Subject | By | Source | When |
---|---|---|---|
A nice short read on a PROTAC approach | dcaf7 | investorshub | 05/01/2023 12:22:38 AM |
Its not about revenue. | Tartiaboy | investorshub | 04/27/2023 7:20:11 PM |
The stock has dropped from the .60 area | Zeppo | investorshub | 04/25/2023 2:14:15 PM |
AML news. | dcaf7 | investorshub | 04/21/2023 5:09:01 PM |
TP53 rules. | Tartiaboy | investorshub | 04/20/2023 12:34:17 PM |
Precipitation in stomach rules. | dcaf7 | investorshub | 04/19/2023 11:35:52 PM |
It is what it is. Another option. | Tartiaboy | investorshub | 04/19/2023 9:23:53 PM |
Now they want you to vote for reverse | dcaf7 | investorshub | 04/19/2023 7:31:48 PM |
Good day for biotech tomorrow? | dcaf7 | investorshub | 04/16/2023 9:28:41 PM |
Thank you | Wolverine3 | investorshub | 04/14/2023 10:46:46 PM |
There is a chance but you need a | dcaf7 | investorshub | 04/14/2023 10:19:10 PM |
Ok, thanks. How about the possibility to displace | Wolverine3 | investorshub | 04/14/2023 9:04:33 PM |
Chance to be used after Gilteritinib? Sure. It | dcaf7 | investorshub | 04/14/2023 8:25:10 PM |
Decaf, do you think TUSP really has a | Wolverine3 | investorshub | 04/14/2023 4:46:46 PM |
Decaf, sounds like youre getting a bit more | spiderman3600 | investorshub | 04/14/2023 3:23:18 PM |
In addition, on Slide 12 you can see | dcaf7 | investorshub | 04/14/2023 2:17:41 PM |
A new redesigned Corporate presentation is available. | dcaf7 | investorshub | 04/14/2023 1:49:54 PM |
It was accelerated approval. Doesn't count much. But | dcaf7 | investorshub | 04/10/2023 6:44:09 PM |
Pirtobrutinib was approved for MCL in January. | Tartiaboy | investorshub | 04/10/2023 5:35:47 PM |
Possible reason for Zilo phase 3 trial termination? | dcaf7 | investorshub | 04/07/2023 1:22:22 PM |
News, Short Squeeze, Breakout and More Instantly...
Aptose Biosciences Inc. Company Name:
APTO Stock Symbol:
NASDAQ Market:
Aptose Biosciences Inc. Website:
SAN DIEGO and TORONTO, June 18, 2024 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral kinase inhibitors to treat hematologic malignancies,...
TUS Monotherapy and TUS+Venetoclax (VEN) Doublet Therapy Show Broad Clinical Activity and Strong Safety Data in relapsed or refractory (R/R) Acute Myeloid Leukemia (AML) and Differentiate TUS from other Investigational Drugs in AML TUS Monotherapy and TUS+VEN Doublet Therapy Active in...
SAN DIEGO and TORONTO, June 03, 2024 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral targeted agents to treat hematologic malignancies, t...